From: Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas
Covariate
Hazard function** (95% confidence intervals)
p-value
Age
1.01 (1.00, 1.02)
.006
Prior chemotherapy
1.02 (0.92, 1.14)
.659
Group B
0.48 (0.35, 0.66)
<.0001
Group C
0.51 (0.40, 0.65)